Last $915.40 MXN
Change Today 0.00 / 0.00%
Volume 0.0
NVSN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
New York
Mexico
Xetra
OTC US
Frankfurt
SIX Swiss Ex
As of 4:09 PM 05/20/13 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NVSN) Snapshot

Open
$915.40
Previous Close
$915.40
Day High
$915.40
Day Low
$915.40
52 Week High
05/15/13 - $926.11
52 Week Low
05/30/12 - $733.00
Market Cap
--
Average Volume 10 Days
1.7K
EPS TTM
--
Shares Outstanding
0.0
EX-Date
02/26/13
P/E TM
--
Dividend
$2.54
Dividend Yield
3.41%
Current Stock Chart for NOVARTIS AG-ADR (NVSN)

novartis ag-adr (NVSN) Latest News

More News

novartis ag-adr (NVSN) Details

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism, respiratory, and other medicines. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines, and blood testing and molecular diagnostics products to prevent the spread of infectious diseases. Its Consumer Health division consists of two divisions, including over-the-counter medicines that offer readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

129,000 Employees
Last Reported Date: 04/24/13
Founded in 1895

novartis ag-adr (NVSN) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.3.4M
President of Institutes for Biomedical Resear...
Total Annual Compensation: $2.0M
Division Head, Novartis Pharmaceuticals and M...
Total Annual Compensation: $2.4M
Division Head of Alcon and Member of Executiv...
Total Annual Compensation: $1.8M
Head of Animal Health, Head of Corporate Resp...
Total Annual Compensation: SFr.1.6M
Compensation as of Fiscal Year 2012.

novartis ag-adr (NVSN) Key Developments

Oxford BioMedica PLC Announces Lentiviral Vector Development and Manufacturing Collaboration with Novartis

Oxford BioMedica plc announced that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica's LentiVector® gene delivery technology. Under the terms of the agreement, Oxford BioMedica will also provide certain process development services and expects to receive between £2.5 million and £4 million from Novartis over the next 12 months. Oxford BioMedica will be responsible for manufacturing several batches of a lentiviral vector encoding CTL019 technology. This vector will be used to transduce patients' immune cells (T-cells) in an ex vivo process before they are re-infused into patients. CTL019 targets a protein called CD19 that is associated with a number of B-cell malignancies including chronic lymphocytic leukemia, B-cell acute lymphocytic leukaemia and diffuse large B-cell lymphoma.

Chicago Joins Suit Against Novartis over Doctor Kickbacks

The city of Chicago is among the local governments named as plaintiff in a lawsuit accusing the Novartis of paying kickbacks to doctors. It's the second civil fraud suit the federal government has launched against the company in a week. The first accuses the company of paying kickbacks to pharmacies to use one of its drugs in exchange for discounts and rebates. The suit alleges that the scheme resulted in Medicare and Medicaid paying millions of dollars in reimbursements. In this second suit, the federal government, 27 states, New York City, the District of Columbia, and Chicago said doctors were paid many millions of dollars to speak about the company drugs, but often did not perform any educational duties at all.

Novartis AG Plans to Cut 300 Jobs at its US Plant in Lincoln, Nebraska

Novartis AG announced it would cut 300 jobs at its US plant in Lincoln, Nebraska, where authorities had detected quality problems.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVSN:MM $915.40 MXN 0.00

NVSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $88.59 USD +0.58
Nestle SA SFr.66.95 CHF 0.00
Pfizer Inc $28.78 USD +0.08
Procter & Gamble Co/The $78.80 USD -0.29
Roche Holding AG SFr.251.00 CHF +4.00
View Industry Companies
 

Industry Analysis

NVSN

Industry Average

Valuation NVSN Industry Range
Price/Earnings 18.9x
Price/Sales 3.1x
Price/Book 2.7x
Price/Cash Flow 20.8x
TEV/Sales 3.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.